Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Net Income towards Common Stockholders (2017 - 2025)

Sutro Biopharma's Net Income towards Common Stockholders history spans 9 years, with the latest figure at -$46.8 million for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 130.64% to -$46.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$180.4 million, a 7418.17% decrease, with the full-year FY2025 number at -$191.1 million, down 7861.62% from a year prior.
  • Net Income towards Common Stockholders hit -$46.8 million in Q4 2025 for Sutro Biopharma, up from -$56.9 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for STRO hit a ceiling of $152.6 million in Q4 2024 and a floor of -$65.3 million in Q1 2025.
  • Historically, Net Income towards Common Stockholders has averaged -$25.2 million across 5 years, with a median of -$38.3 million in 2021.
  • Biggest five-year swings in Net Income towards Common Stockholders: tumbled 322.82% in 2022 and later surged 391.29% in 2024.
  • Tracing STRO's Net Income towards Common Stockholders over 5 years: stood at -$38.1 million in 2021, then increased by 9.26% to -$34.6 million in 2022, then soared by 189.8% to $31.1 million in 2023, then surged by 391.29% to $152.6 million in 2024, then crashed by 130.64% to -$46.8 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for STRO at -$46.8 million in Q4 2025, -$56.9 million in Q3 2025, and -$11.5 million in Q2 2025.